WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Vaccinex Inc - Growth / Value Index


VCNX - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Book Value in last 3 years is trending down
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -21.57 -116.69 -206438.00 %
Price to Book -308.11 -1111.48 -515665.41 % -2.14
Price to Sales -1096.75 4142.96 101666 %
Enterprise Value to EBITDA Multiple -0.354 -117.37 -46974.53 %


VCNX - Profitability Highlights

Profitability Analysis

   Strong Return On Capital Employed of 996.02
   Company Earning excess return
   During the past twelve months, the company has given a strong Net Margin of 5083.61%
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 0 0 0 % 0
Return On Asset -522.64 -606.22 -144.05 % -91.35
Net Profit Margin 5083.61 -3550.32 50.73 % 859.33
Operating Profit Margin 6253.28 -3712.26 48.72 % 1292.23
EBITDA Margin 5782.10 -3528.06 50.75 % 1285.36


Highlights
Market Cap8777.02 K
Enterprise Value7489.02 K
Price/Book TTM-308.11
Outstanding Share1584.30 K
Float/ Outstanding Share30.14%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score-150.84
Sloan Ratio-1.04
Peter Lynch Fair Value0


VCNX - Growth Highlights

Growth Analysis

   STRONG JUMP IN NET SALE : YoY growth
   Tsr Growth Index - Very Poor Score of 5.00
   Quarterly sales in last 5 Quarter is trending down
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue -366000.00 125.45 % %
Gross Profit -36500.00 107.27 % %
EBITDA -21162.50 K 11.04 % 50.81 %
Net Profit -18606.00 K 11.09 % 0 %
EPS -0.257 99.95 % NA


VCNX - Stability Highlights

Stability Analysis

   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of -150.85 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -22011.00
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -0.107 -263.73 % -0.096
Cash Ratio 0.259 -89.70 %
Quick Ratio 0 0 % 0.566
Shareholders Equity -63.65 -197.77 %
Debt to EBITDA -0.0113 34.38 %


Historical Valuation Ratios of Vaccinex Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Vaccinex Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Vaccinex Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Vaccinex Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)